Sar­to­rius buys ma­jor­i­ty stake in Ger­man man­u­fac­tur­ing play­er; Cerev­el Ther­a­peu­tics ends the week on a high note, with $350M raise

Sar­to­rius Ste­d­im Biotech ac­quired a ma­jor­i­ty stake in Ger­many-based Cell­Genix GmbH, the com­pa­nies an­nounced Fri­day.

Sar­to­rius has ac­quired 51% of the com­pa­ny for $118.3 mil­lion and an­nounced the plan to ac­quire the re­main­ing shares of the com­pa­ny at the be­gin­ning of 2023 and 2026.

Cell­Genix was start­ed at the Uni­ver­si­ty Med­ical Cen­ter of Freiburg in 1994 and cur­rent­ly em­ploys 70 peo­ple. The com­pa­ny gen­er­at­ed $23.6 mil­lion in sales in 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER